InsidersTradesSigma
Follow the VERACYTE INC COM stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €3.4bn. The latest transaction was disclosed on 18 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: KARIN EASTHAM. Every trade is free.
Analysts rate VERACYTE INC COM Buy (bullish), based on 11 analysts. Average price target: US$57.82.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Veracyte Inc is a molecular diagnostics company that provides tests to aid clinical decision-making in healthcare. It is listed on NASDAQ under the symbol VCYT.